← Back to Clinical Trials
Recruiting Phase 2 NCT07073417

A Study to Compare XW003 Injection and Semaglutide Injection in Chinese Adults With Obesity (SLIMMER-UP-SWITCH)

Trial Parameters

Condition Obesity
Sponsor Hangzhou Sciwind Biosciences Co., Ltd.
Study Type INTERVENTIONAL
Phase Phase 2
Enrollment 160
Sex ALL
Min Age 18 Years
Max Age 75 Years
Start Date 2025-07-28
Completion 2027-02-27
Interventions
XW003 injectionsemaglutide injection

Brief Summary

The aim of the study is to compare the efficacy and safety of XW003 injection versus semaglutide injection in Chinese adults with obesity

Eligibility Criteria

Inclusion Criteria: * BMI≥30 kg/m2 at screening, waist circumference ≥90 cm for men and ≥85 cm for women. * Weight change of less than 5% within 3 months prior to screening (self-reported). Exclusion Criteria: * Diagnosis of obesity due to endocrine disorders or a single gene mutation, including but not limited to hypothalamic obesity, pituitary obesity, Cushing's syndrome, hypothyroidic obesity (except for those with normal thyroid function at screening and expected to remain unchanged throughout the trial period after at least 3 months of thyroid hormone replacement therapy), insulinoma, acromegaly. * History of bariatric surgery or planning to undergo bariatric surgery or use other weight-loss drugs or devices during the trial (except acupuncture for weight loss, liposuction, or abdominal fat removal for more than one year before screening; Except the removal or expulsion of the airbag in the stomach for more than 1 year before screening. * Diagnosis with any type of diabetes (excep

Related Trials